Organizing Committee
OCM Member
Founder and Chairman Emeritus, Immunology
Vaccinogen Inc , USA
Biography :

Dr. Hanna is a co-founder of Vaccinogen, Inc., the discoverer and developer of OncoVAX, Vaccinogen’s lead project, and a pioneer in the field of cancer vaccines. He also developed and obtained FDA approval for TICE BCG for treatment of carcinoma in situ ("CIS") bladder cancer which remains the standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. Dr. Hanna has not only proven his capabilities as discoverer and developer of clinically beneficial biotherapeutics, but also has raised over $300 million for the final clinical development of OncoVAX. As the director of the National Cancer Institutes, Frederick Cancer Research Center, between 1975 – 1983, he created a center of research excellence and managed over 2,000 technologists consisting of hundreds of MDs and PhDs. A special committee of the National Cancer Advisory Board selected him for the above responsibilities. He previously served as Chairman (Emeritus) and Chief Scientific Officer of Intracel Resources, an integrated biopharmaceutical company that developed cancer vaccines and immunotherapeutic and diagnostic products for both cancers and infectious diseases. Dr. Hanna also served as President and Chief Executive Officer of PerImmune, Inc. before it and Intracel Corp. merged in 1998. From 1985 to 1994, he was the Chief Operating Officer of Organon Teknika Biotechnology Research Institute and Senior Vice President of Organon Teknika Corporation, a subsidiary of Akzo Nobel, N.V., The Netherlands. Prior to that, he was Director of the National Cancer Institute, Frederick Cancer Research Center. Dr. Hanna received a doctoral degree in experimental pathology and immunology from the University of Tennessee. He has over 225 publications to his credit, has 10 patents in immunotherapy and has been the recipient of numerous honors.

Research Interest :

Immunology and Immunotherapy.

OCM Member
Bawa Biotech LLC , USA
Biography :

Raj Bawa is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm based in Ashburn, VA, USA that he founded in 2002. He is an inventor, entrepreneur, professor and registered patent agent licensed to practice before the U.S. Patent & Trademark Office. Trained as a biochemist and microbiologist, he has been an active researcher for over two decades. He has extensive expertise in pharmaceutical sciences, biotechnology, nanomedicine, drug delivery and biodefense, FDA regulatory issues, and patent law. Since 1999, he has held various positions at Rensselaer Polytechnic Institute in Troy, NY, where he is currently an adjunct professor of biological sciences and where he received his doctoral degree in three years (biophysics/biochemistry). Since 2004, he has been an adjunct professor of natural and applied sciences at NVCC in Annandale, VA. He is a scientific advisor to Teva Pharmaceutical Industries, Ltd., Israel. He has served as a principal investigator of National Cancer Institute SBIRs and reviewer for both the NIH and NSF. In the 1990s, Dr. Bawa held various positions at the US Patent & Trademark Office, including primary examiner for 6 years. He is a life member of Sigma Xi, co-chair of the Nanotech Committee of the American Bar Association and serves on the global advisory council of the World Future Society. He is frequently interviewed by the media and appeared in such publications as Nature, MIT Technology Review, American Chemical Socitye CE&N, Business Review, etc. He has authored over 100 publications, co-edited four texts and serves on the editorial boards of 17 peer-reviewed journals, including serving as a Special Associate Editor of Nanomedicine (Elsevier) and an Editor-in-Chief of the Journal of Interdisciplinary Nanomedicine (Wiley). Some of Dr. Bawa’s awards include the Innovations Prize from the Institution of Mechanical Engineers, London, UK (2008); Appreciation Award from the Undersecretary of Commerce, Washington, DC (2001); the Key Award from Rensselaer’s Office of Alumni Relations (2005); and Lifetime Achievement Award from the American Society for Nanomedicine (2014).

Research Interest :

Since 2002, Dr. Bawa is listed on the official “Roster of Attorneys and Agents” maintained by the US Patent & Trademark Office (PTO) as a registered patent agent in good standing, licensed to practice before the PTO.

OCM Member
Dean (Students Affairs), Professor of Medical Microbiology, Immunology and Parasitology, Immunology and Parasitology
Avalon University School of Medicine , Netherlands
Biography :

M V Raghavendra Rao, PhD, worked as Professor of microbiology, parasitology, immunology and Epidemiology in many universities in India, China, Nepal, Libya, and Philippines. Currently, he is working at Avalon University School of Medicine, Curacao, Netherland Antilles. He has more than 40 years of teaching and research experience. He supervised 3 students for PhD, and 8 students for MPhil. He authored 18 text books. Three universities appointed him as their advisor and 3 universities acknowledged him with fellowships.

Research Interest :

Dr Rao authored and Chief Editor for 11 Medical textbooks. Professor Rao was an invited Keynote speaker for more than 40 international conferences all over the globe.

OCM Member
President
T & L de Beaumont Bonelli for cancer research , Italy
Biography :

Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006 -. Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). His researches have been concerned with the characterization of specific virus-induced tumour antigens, which were the "finger-prints" left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas

Research Interest :

Microbiology, cancer

OCM Member
Professor, Immunology
Federal University of Rio de Janeiro , Brazil , Brazil
Biography :

Graduated in Biological Science (1990), Master in Parasitary Biology by Instituto Oswaldo Cruz-FIOCRUZ (1995), PhD in Sciences by the Institute of Microbiology Prof. Paulo de Góes of the Federal University of Rio de Janeiro (2000), Post-doctorate at the Laboratory of Immunopharmacology of the Department of Physiology and Pharmacodynamics of the Oswaldo Cruz Institute (2000-2002) and in the Program of Cell Biology of the National Jewish Medical and Research Center of Denver, Colorado, USA (2002-2004). He is currently Associate Professor I of the Immunobiology Program of the Biophysics Institute Carlos Chagas Filho of the Federal University of Rio de Janeiro. He has experience in Immunology, with emphasis on Cellular Immunology, Immunoparasitology and Immunomodulation, working mainly in the following subjects: Chagas disease, leishmaniasis, cryptococcosis,

Research Interest :

Experiente in Immunology, with enphasis in Cellular Immunology, Immunomodulation, Immunoparasitology and acting in following topics: Chagas diseases, Leishmaniasis, Cryptococcosis, Apoptosis and Inflammation

OCM Member
Professor, Immunology & Medicine
MINO MGUPP , Russia
Biography :

Dr Sergey Suchkov, MD, PhD. Professor in Immunology & Medicine. Director, Center for Personalized Medicine, Sechenov University and Chair,Dept for Translational Medicine, Moscow Engineering Physical Institute (MEPhI). Born on 11 Jan 1957, Astrakhan, Russia; two sons. Education: MD, Astrakhan State Medical University, Russia, 1980; PhD, I.M.Sechenov First Moscow State Medical University, 1985; Doctor Degree, National Institute of Immunology, Russia, 2001. Positions held: Post Doc Research Associate, Institute of Medical Enzymology; Head of the Lab of Immunology, Helmholtz Eye Research Institute in Moscow; Trainee, Laboratory of Immunology, NEI, Bethesda, MD, USA; Chair, Department for Clinical Immunology, Moscow Clinical Research Institute; Executive Secretary-in-Chief of the Editorial Board, Biomedical Science International journal. Honours: Secretary General, United Cultural Convention, Cambridge, UK. Memberships: New York Academy of Sciences, USA; ISPM, Tokyo, Japan; PMC, Washington, DC, USA; ACS, USA; AMEE, Dundee, UK; AHA, USA; EPMA, Brussels.

Research Interest :

Member of the Editorial Boards of: ? EPMA J. (Springer); ? Personalized Medicine Universe (Elsevier); ? Open J. Autoimmunity (Science Publishers Group) ? American J. of Cardiovascular Research (USA) ? Remedium (Russia-Japan) ? Jacobs J.Biomarkers (USA) Member, EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; Member, ISPM (International Society for Personalized Medicine), Tokyo, Japan; Member, PMC (Personalized Medicine Coalition), Washington, USA; Secretary General, UCC (United Cultural Convention), Cambridge, UK;

OCM Member
Ben Gurion University of Negev , Israel
Biography :

Noah Isakov is a Professor of Immunology in the Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, at Ben Gurion University of the Negev, in Beer Sheva, Israel, where he holds the Joseph H Krupp Chair in Cancer Immunobiology. He obtained his PhD from the Weizmann Institute of Science in Rehovot, Israel (1981) and worked as a postdoctoral researcher at the University of Minnesota in Minneapolis, MN (1981-1983) and the Scripps Research Institute in La Jolla, CA (1983-1987). He performed sabbaticals at the NICHD, National Institutes of Health in Bethesda, MD (1993-1995), the Oklahoma Medical Research Foundation in Oklahoma City, OK (2003-2004), where he held the Esther Greenberg Honors Chair in Biomedical Research, and the Otago University in Dunedin, New Zealand (2015).

Research Interest :

Member of the Editorial Boards of: ? EPMA J. (Springer); ? Personalized Medicine Universe (Elsevier); ? Open J. Autoimmunity (Science Publishers Group) ? American J. of Cardiovascular Research (USA) ? Remedium (Russia-Japan) ? Jacobs J.Biomarkers (USA) Member, EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; Member, ISPM (International Society for Personalized Medicine), Tokyo, Japan; Member, PMC (Personalized Medicine Coalition), Washington, USA; Secretary General, UCC (United Cultural Convention), Cambridge, UK;

OCM Member
Professor, Shraga Segal Department of Microbiology, Immunology and Genetics
Ben Gurion University of Negev , Israel
Biography :

Yaffa Mizrachi Nebenzahl has completed her PhD at The Weizmann Institute, Israel in 1985. She is the Head of the Molecular Microbiology Laboratory in The Shraga Segal Department of Microbiology, Immunology and Genetics at the Faculty of Health Sciences in Ben Gurion University of the Negev, Israel.

Research Interest :

Immunology, molecular biology, infectious diseases, bio chemistry, pneumonia, innate Immunity.

OCM Member
King Fahad Medical City , Saudi Arabia
Biography :

Aziz Alami Chentoufi is a Consultant and Head of Immunology/Serology/HLA section at Pathology and Clinical Laboratory Medicine, King Fahad Medical City (KFMC). He is also an Assistant Professor of Immunology at Faculty of Medicine, King Saud Ibn AbdulAziz University. He is the Chairperson of Research Committee of PCLMA-KFMC. He is the Diplomate of the American Board of Medical laboratory Immunology D(ABMLI ), Fellow of the Association of Clinical Sciences (FACSc), accredited by the European Society of Translational Medicine (PCTM) and Fellow of the Academy of translational Medicine (FacadTM). He received his Ph.D. in Biomedical Sciences (Tolerance induction to xenogenic and allogenic antigens using monoclonal antibody anti-igM and anti-IgD) from the University Catholic of Louvain, Brussels, Belgium in 1999. He has done postdoctoral fellowship at McGill University, Montreal, Canada from 1999 to 2004 where he worked on immunogenetic of type 1 Diabetes and gene therapy for graft versus host disease then he was appointed as specialist at the University of California Irvine-Medical Center, Irvine, California, USA in 2006 where he was a key investigator in the development of mucosal vaccine against herpes simplex virus type 1 and 2.

Research Interest :

He is an independent Immunologist with a national and international reputation in vaccine development against both infectious and autoimmune diseases. He is well-integrated into the scientific community within the United States as well as Europe and Saudi Arabia and he is actively involved in a number of professional societies including American Society of Histocompatibility and Immunogenetic (ASHI), Association of Clinical Scientist, Canadian Society of Immunology and The Federation of Clinical Immunology Societies (FOCIS). He is PI and Co-PI in a number of research grant proposals and associate editor in many scientific journals and has more than 50 publications in high impact factor journals.

OCM Member
Head of Scientific Research Board, Internal medicine-rheumatologist
University of Belgrade , Serbia
Biography :

Ljudmila Stojanovich received her Ph.D. in Medicine, with the thesis “Neuropsychiatric manifestations in patients with Systemic Lupus Erythematosus” in 1999. She is the scientific director in the Bezhanijska Kosa, University Medical Center of Belgrade University, where she is currently a Research Professor. Dr. Stojanovich’s research focuses on Systemic Lupus Erythematosus, Antiphospholipid Syndrome, and Vaccination in patients with Autoimmune Rheumatic diseases. She is an author of three monographs and of about 250 articles on various aspects of Autoimmune Rheumatic disorders, published in international and domestic journals and in conference proceedings. She is in Editorial Boards (Editorial Boards LUPUS (LONDON). /Reviewer in the “CURRENT CONTENSTS” or “Science citation index”, like LUPUS REWIEWER DATABAS, Cellular and Molecular Neurobiology, The Journal of Vaccine <jvac@elsevier.com , The Journal of Rheumatology, Allergologia et Immunopathologia and others. She is a member of number International Project, like of “the European Forum on Antiphospholipid Antibodies”, “Multicenter studies antiphospholipid antibodies, infections and autoimmune diseases”. She is a mentor/ Supervisor ships a numbers of post-doc students. She was in Invited Speaker for many lectures in Congresses and Symposia; organizer and Chairman of many Workshops, Seminars and Symposia; member of the Steering Committee of the “(EULAR) recommendations for vaccination in patients with auto-immune inflammatory rheumatic diseases (AIIRD)”, and EULAR Honorary Member; chairman in the International Congress “Antiphospholipid syndrome (Hughes syndrome) importance of multidisciplinary approaches- 30 years since definition”, 2013, “GRANT 2015” of the EUROPEAN STROKE CONFERENCE » for “excellent research in cerebrovascular diseases reviewed by the Scientific and programmer Committees”, and presented at the 24th Annual Meeting; Vienna, may, 2015. Member of ILLUMINATE steering committee: the phase 3 lupus ILLUMINATES clinical trials of Tabalumab/ Eli Lilly and Company., MD, PhD, FRCP, are willing to serve as a consultant to Lilly Research Laboratories, a division of Eli Lilly and Company (“Lilly”), in connection with the development of Tabalumab also known as LY2439821. Co- Chairman and the lector “LUPUS ACADEMY EASTERN EUROPEAN ROADSHOW of EULAR«: Belgrade, 18TH MARCH 2016, www.lupus-academy.org. Member of the American Association for the Advancement of Science (AAAS) from 2017. Professor Ljudmila Stojanovich’ Impact Point is 300.14, and number of citattions is 1,444.

Research Interest :

Pharmacology, Internal medicine-rheumatology

Allied Academies Global Conference Directory

Mail us at

Program Enquiry
immunology@alliedgathering.org
Sponsors/Exhibiting/Advertising
immunologycongress@alliedgathering.com
General Queries
immunology@alliedgathering.org
More details about sponsorship:sponsors@alliedacademies.com

Authorization Policy


Copyright © 2023-2024 Allied Academies, All Rights Reserved.